STOCK TITAN

Corcept Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Corcept Therapeutics (NASDAQ: CORT) will present at two upcoming investor conferences. The Jefferies London Healthcare Conference is on November 16, 2021, at 5:00 pm GMT, featuring a fireside chat format. The Evercore ISI 4th Annual HealthCONx Conference is scheduled for November 30, 2021, at 11:20 am EST, also in a fireside chat format.

Corcept specializes in developing drugs for serious metabolic, oncologic, and neuropsychiatric disorders by modulating cortisol. Its product Korlym® is FDA-approved for Cushing’s syndrome, supported by a robust portfolio of proprietary cortisol modulators.

Positive
  • None.
Negative
  • None.

MENLO PARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effects of the hormone cortisol, today announced that the company will present at the following investor conferences:

Jefferies London Healthcare Conference

  • Date: Tuesday, November 16, 2021
  • Presentation Time: 5:00 pm GMT
  • Format: Fireside Chat

Evercore ISI 4th Annual HealthCONx Conference

  • Date: Tuesday, November 30, 2021
  • Presentation Time: 11:20 am EST
  • Format: Fireside Chat

About Corcept Therapeutics
Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved by the U.S. Food and Drug Administration for patients with Cushing’s syndrome. Corcept has discovered a large portfolio of proprietary compounds that selectively modulate the effects of cortisol. The company owns extensive United States and foreign intellectual property covering the composition of its selective cortisol modulators and the use of cortisol modulators to treat a variety of serious disorders.

CONTACT:
Corcept Therapeutics
Investor Relations
ir@corcept.com
www.corcept.com


FAQ

What dates will Corcept Therapeutics present at investor conferences?

Corcept Therapeutics will present on November 16, 2021, at the Jefferies London Healthcare Conference, and on November 30, 2021, at the Evercore ISI 4th Annual HealthCONx Conference.

What is the presentation format for Corcept's upcoming conferences?

Both presentations will be in a fireside chat format.

What is the significance of Korlym® by Corcept?

Korlym® is the first drug approved by the FDA for treating Cushing’s syndrome, highlighting Corcept's focus on cortisol modulation.

What disorders does Corcept Therapeutics focus on?

Corcept Therapeutics focuses on severe metabolic, oncologic, and neuropsychiatric disorders through cortisol modulation.

What is the stock symbol for Corcept Therapeutics?

The stock symbol for Corcept Therapeutics is CORT.

Corcept Therapeutics Inc.

NASDAQ:CORT

CORT Rankings

CORT Latest News

CORT Stock Data

5.52B
104.11M
11.52%
86.9%
19.75%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
MENLO PARK